Erythema nodosum–like eruption in the setting of sorafenib therapy

Background: Sorafenib, a small molecule inhibitor of RAF kinase and VEGFR-2/PDGFR-beta, is approved for use in several cancers. Numerous cutaneous adverse events from sorafenib therapy have been reported. To the best of our knowledge, we report the first case of erythema nodosum (EN)–like eruption concurrent with sorafenib therapy.